Lilly launches lower-price weight loss drug without injector pen - CNN
Aug 27, 2024 · Eli Lilly is making tirzepatide, branded as Zepbound for weight loss, available in vials for patients who pay out-of-pocket.
Eli Lilly to sell Zepbound directly to consumers without ... - ABC News
Aug 27, 2024 · Eli Lilly, the maker of Zepbound, announced Tuesday it will begin selling the weight loss drug directly to consumers through the company's direct pharmacy, LillyDirect.
FDA approves Zepbound® (tirzepatide) as the first and only …
INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound ® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. 1 Zepbound may help adults with moderate-to-severe obstructive sleep apnea and obesity improve their ...
News Release - Eli Lilly and Company
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Zepbound ® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an on-label prescription, significantly expanding the supply of Zepbound in response to high demand.
FDA Approves First Medication for Obstructive Sleep Apnea - U.S.
Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in...
FDA Approves Lilly's Zepbound™ (tirzepatide ... - Eli Lilly and …
Nov 8, 2023 · Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.
Zepbound price cut: Eli Lilly lowers cost of weight loss drug - NBC News
Aug 27, 2024 · Drugmaker Eli Lilly is significantly lowering the prices of the two lowest doses of its blockbuster weight loss drug Zepbound, it said Tuesday, in a move to expand access and …
Lilly's Zepbound® (tirzepatide) superior to Wegovy® …
Dec 4, 2024 · SURMOUNT-5 compared Zepbound, a dual GIP and GLP-1 receptor agonist, to Wegovy, a mono GLP-1 receptor agonist in adults living with obesity without diabetes. INDIANAPOLIS, Dec. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial.
Zepbound: Eli Lilly releases new, cheaper form of weight loss drug - CNBC
Aug 27, 2024 · Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to reach millions of patients without insurance coverage for the popular...
Eli Lilly slashes prices of weight-loss drug Zepbound for ... - CBS News
Aug 28, 2024 · Drugmaker Eli Lilly said Tuesday it will sell single-use vials of its weight-loss drug Zepbound at a fraction of the price of its pens, amid skyrocketing demand among Americans for...
- Some results have been removed